Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Stopped early · Phase 3
Conditions studied: Osteoporosis, Prostate Cancer
In brief
RATIONALE: Zoledronate may prevent bone loss associated with long term androgen deprivation therapy. It is not yet known whether zoledronate combined with calcium is more effective than calcium alone in preventing bone loss. PURPOSE: Randomized phase III trial to compare the effectiveness of zoledronate combined with calcium with that of calcium alone in preventing bone loss in patients with stage III or stage IV prostate cancer who have received long-term androgen deprivation therapy.
Key facts
- Study ID
- NCT00058188
- Run by
- Northwestern University
- People needed
- 53
- Starts
- 2003-03-01
- Expected to finish
- 2008-11-01
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Northwestern University — Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago — Chicago, Illinois, United States
- John H. Stroger Hospital of Cook County — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.